197 related articles for article (PubMed ID: 25853231)
1. mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma.
Zhang W; Ding ML; Zhang JN; Qiu JR; Shen YH; Ding XY; Deng LF; Zhang WB; Zhu J
Sci Rep; 2015 Apr; 5():9604. PubMed ID: 25853231
[TBL] [Abstract][Full Text] [Related]
2. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage.
Berman SD; Calo E; Landman AS; Danielian PS; Miller ES; West JC; Fonhoue BD; Caron A; Bronson R; Bouxsein ML; Mukherjee S; Lees JA
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11851-6. PubMed ID: 18697945
[TBL] [Abstract][Full Text] [Related]
3. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.
Li H; Han X; Yang S; Wang Y; Dong Y; Tang T
Oncogene; 2021 Apr; 40(15):2785-2802. PubMed ID: 33716296
[TBL] [Abstract][Full Text] [Related]
4. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma.
Thomas DM; Johnson SA; Sims NA; Trivett MK; Slavin JL; Rubin BP; Waring P; McArthur GA; Walkley CR; Holloway AJ; Diyagama D; Grim JE; Clurman BE; Bowtell DD; Lee JS; Gutierrez GM; Piscopo DM; Carty SA; Hinds PW
J Cell Biol; 2004 Dec; 167(5):925-34. PubMed ID: 15583032
[TBL] [Abstract][Full Text] [Related]
5. Capsaicin induces apoptosis in human osteosarcoma cells through AMPK-dependent and AMPK-independent signaling pathways.
Ying H; Wang Z; Zhang Y; Yang TY; Ding ZH; Liu SY; Shao J; Liu Y; Fan XB
Mol Cell Biochem; 2013 Dec; 384(1-2):229-37. PubMed ID: 24005536
[TBL] [Abstract][Full Text] [Related]
6. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells.
Rubio R; Abarrategi A; Garcia-Castro J; Martinez-Cruzado L; Suarez C; Tornin J; Santos L; Astudillo A; Colmenero I; Mulero F; Rosu-Myles M; Menendez P; Rodriguez R
Stem Cells; 2014 May; 32(5):1136-48. PubMed ID: 24446210
[TBL] [Abstract][Full Text] [Related]
7. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1).
Pereira BP; Zhou Y; Gupta A; Leong DT; Aung KZ; Ling L; Pho RW; Galindo M; Salto-Tellez M; Stein GS; Cool SM; van Wijnen AJ; Nathan SS
J Cell Physiol; 2009 Dec; 221(3):778-88. PubMed ID: 19746444
[TBL] [Abstract][Full Text] [Related]
8. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
Akeno N; Miller AL; Ma X; Wikenheiser-Brokamp KA
Oncogene; 2015 Jan; 34(5):589-99. PubMed ID: 24469052
[TBL] [Abstract][Full Text] [Related]
9. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
10. TRIM14 regulates cell proliferation and invasion in osteosarcoma via promotion of the AKT signaling pathway.
Xu G; Guo Y; Xu D; Wang Y; Shen Y; Wang F; Lv Y; Song F; Jiang D; Zhang Y; Lou Y; Meng Y; Yang Y; Kang Y
Sci Rep; 2017 Feb; 7():42411. PubMed ID: 28205534
[TBL] [Abstract][Full Text] [Related]
11. Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells.
Wang JY; Wu PK; Chen PC; Lee CW; Chen WM; Hung SC
Stem Cells Transl Med; 2017 Feb; 6(2):512-526. PubMed ID: 28191765
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of male germline stem cell differentiation reveals a role for the p53-mTORC1 pathway in spermatogonial maintenance.
Xiong M; Ferder IC; Ohguchi Y; Wang N
Cell Cycle; 2015; 14(18):2905-13. PubMed ID: 26177380
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
[TBL] [Abstract][Full Text] [Related]
15. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
[TBL] [Abstract][Full Text] [Related]
16. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
Jin W; Zhou L; Yan B; Yan L; Liu F; Tong P; Yu W; Dong X; Xie L; Zhang J; Xu Y; Li C; Yuan Q; Shan L; Efferth T
J Cell Mol Med; 2018 Sep; 22(9):4423-4436. PubMed ID: 29993186
[TBL] [Abstract][Full Text] [Related]
17. p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.
Cam M; Bid HK; Xiao L; Zambetti GP; Houghton PJ; Cam H
J Biol Chem; 2014 Feb; 289(7):4083-94. PubMed ID: 24366874
[TBL] [Abstract][Full Text] [Related]
18. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas.
Basu-Roy U; Seo E; Ramanathapuram L; Rapp TB; Perry JA; Orkin SH; Mansukhani A; Basilico C
Oncogene; 2012 May; 31(18):2270-82. PubMed ID: 21927024
[TBL] [Abstract][Full Text] [Related]
19. EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.
Cheng DD; Li SJ; Zhu B; Zhou SM; Yang QC
J Exp Clin Cancer Res; 2018 Mar; 37(1):50. PubMed ID: 29510727
[TBL] [Abstract][Full Text] [Related]
20. Human osteosarcoma CD49f(-)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity.
Ying M; Liu G; Shimada H; Ding W; May WA; He Q; Adams GB; Wu L
Oncogene; 2013 Sep; 32(36):4252-63. PubMed ID: 23045288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
